Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Michael Pacold

New York University School of Medicine, Department: Radiation Diagnostic/oncology

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Raze Therapeutics

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Dr. Pacold has an interest in Raze Therapeutics, which develops one-carbon (1C) metabolism therapeutics to treat cancer. In this research, Dr. Pacold will test the hypothesis that a serine synthesis pathway metabolite coordinates the fate of one-carbon units (Aim 1).

Listed Research Project
Small molecule approaches to studying tumor metabolism

Project Narrative Tumor cells rewire their metabolism to produce a steady supply of molecular building blocks needed for their survival, growth, and proliferation. Antimetabolite chemotherapeutics, which inhibit the altered metabolism of tumors, have a long track record of improving the survival of patients with cancer. Yet, only one new class of antimetabolites has entered clinical trials in the past decade. I will develop techniques for systematically identify novel metabolic enzyme inhibitors to advance our understanding of metabolism in the laboratory, and to serve as proof of concept for novel antimetabolites that might be useful in the treatment of cancer.� �

Filed on September 13, 2017.

Tell us what you know about Michael Pacold's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page